Small-cell lung cancer arising after chemotherapy for a patient with lymphoma of pulmonary mucosa-associated lymphoid tissue-a case report.
A 76-year-old woman was admitted to our hospital with infiltrations evident in the right lower lobe on chest computed tomography. Bronchoscopic biopsy showed lymphoma of mucosa-associated lymphoid tissue (MALT). Lymphoma of the pulmonary MALT became enlarged at 8 months after diagnosis and dyspnea developed. Four courses of chemotherapy(rituximab+ cladribine)resulted in a partial response. However, 14 months after the chemotherapy, she developed multiple lung and liver tumors accompanied by disseminated intravascular coagulation syndrome. A histological examination of bone marrow aspiration showed small cell carcinoma. We administered one course of carboplatin and etoposide, but bone marrow suppression was so severe that further chemotherapy was precluded. To our knowledge, this is a rare case of small cell lung cancer arising from the treatment of lymphoma of pulmonary MALT.
Nakao
Makoto
M
Department of Medical Oncology and Immunology, Nagoya City University School of Medical Sciences, Mizuho-ku, Nagoya, Japan.
Oguri
Tetsuya
T
Maeno
Ken
K
Kusumoto
Shigeru
S
Ota
Chiharu
C
Takakuwa
Osamu
O
Uemura
Takehiro
T
Ozasa
Hiroaki
H
Iwashima
Yasuhito
Y
Miyazaki
Mikinori
M
Kutsuna
Takeo
T
Nakamura
Atsushi
A
Inagaki
Hiroshi
H
Sato
Shigeki
S
Ueda
Ryuzo
R
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001706:Biopsy; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use; D017338:Cladribine / Q000008:administration & dosage / Q000627:therapeutic use; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018442:Lymphoma, B-Cell, Marginal Zone / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D009092:Mucous Membrane / Q000187:drug effects; D016609:Neoplasms, Second Primary / Q000188:drug therapy*; D000069283:Rituximab; D055752:Small Cell Lung Carcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D014057:Tomography, X-Ray Computed
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D017338:Cladribine; D000069283:Rituximab; D005047:Etoposide; D016190:Carboplatin